Plain-English translation of NCT04211389 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested ARQ-151 cream, a new topical treatment applied once daily to the skin, to see if it could safely and effectively reduce symptoms of chronic plaque psoriasis. The study compared the active medication to a placebo cream (a cream with no active ingredient) over 8 weeks. Participants included people ages 2 and older who had been diagnosed with plaque psoriasis.
Chronic plaque psoriasis is a long-lasting skin condition that causes red, thick patches and can significantly affect quality of life. This medication was being studied to see if a new treatment approach could help people manage their symptoms more effectively.
Participants received either the active medication or a placebo cream and applied it once daily to their affected skin areas for 8 weeks. Over that time, they attended visits where the research team examined their skin and checked on any side effects or changes in their psoriasis. Participants were randomly assigned to receive either the real medication or placebo, and neither they nor the study staff knew which treatment they were receiving until the study ended.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States